818 related articles for article (PubMed ID: 16784930)
1. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
2. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
[TBL] [Abstract][Full Text] [Related]
3. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.
Kyrzopoulos S; Adamopoulos S; Parissis JT; Rassias J; Kostakis G; Iliodromitis E; Degiannis D; Kremastinos DT
Int J Cardiol; 2005 Mar; 99(3):409-13. PubMed ID: 15771921
[TBL] [Abstract][Full Text] [Related]
4. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
5. Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine.
Cavusoglu Y; Tek M; Birdane A; Ata N; Demirustu C; Gorenek B; Unalir A; Timuralp B
Int J Cardiol; 2008 Jul; 127(3):e188-91. PubMed ID: 17884200
[TBL] [Abstract][Full Text] [Related]
6. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone.
Nanas JN; Papazoglou PP; Terrovitis JV; Kanakakis J; Dalianis A; Tsolakis E; Tsagalou EP; Agrios N; Christodoulou K; Anastasiou-Nana MI
Am J Cardiol; 2004 Nov; 94(10):1329-32. PubMed ID: 15541261
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
Zemljic G; Bunc M; Yazdanbakhsh AP; Vrtovec B
J Card Fail; 2007 Aug; 13(6):417-21. PubMed ID: 17675054
[TBL] [Abstract][Full Text] [Related]
9. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
[TBL] [Abstract][Full Text] [Related]
10. Effects of levosimendan on right ventricular function in patients with advanced heart failure.
Parissis JT; Paraskevaidis I; Bistola V; Farmakis D; Panou F; Kourea K; Nikolaou M; Filippatos G; Kremastinos D
Am J Cardiol; 2006 Dec; 98(11):1489-92. PubMed ID: 17126656
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
Sargento L; Brito D; Matias JS; Madeira H
Rev Port Cardiol; 2007; 26(7-8):717-26. PubMed ID: 17939581
[TBL] [Abstract][Full Text] [Related]
13. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
[TBL] [Abstract][Full Text] [Related]
14. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure.
Moertl D; Berger R; Huelsmann M; Bojic A; Pacher R
Eur J Heart Fail; 2005 Dec; 7(7):1156-63. PubMed ID: 16084762
[TBL] [Abstract][Full Text] [Related]
15. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
[TBL] [Abstract][Full Text] [Related]
16. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
Avgeropoulou C; Andreadou I; Markantonis-Kyroudis S; Demopoulou M; Missovoulos P; Androulakis A; Kallikazaros I
Eur J Heart Fail; 2005 Aug; 7(5):882-7. PubMed ID: 15921958
[TBL] [Abstract][Full Text] [Related]
17. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
18. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
[TBL] [Abstract][Full Text] [Related]
19. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
[TBL] [Abstract][Full Text] [Related]
20. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
